Skip to main content
LOGO(small) - Queen's University Belfast
  • Our twitter
  • Our facebook
  • Our
  • Our
SEARCH SEARCH
LOGO(large) - Queen's University Belfast

The Patrick G Johnston Centre for Cancer Research

  • Home
  • Our Science
  • Education
    • Postgraduate Research
    • Postgraduate Taught
    • Clinical Academic Training
    • Summer Research Programme
    • Undergraduate
    • Princess Margaret Cancer Centre
  • Impact
    • Videos
    • Seminars and Events
    • Research Engagement
    • Industry and Innovations
    • Bulletins and Annual Reports
  • Opportunities
    • Academic Posts
    • Postdoctoral
    • PhD Opportunities
  • Contact Us
    • Academic Staff
    • Administrative Staff
    • Technical Staff
    • Clinical Academic Training Programme
    • Clinical Research Fellows
    • Honorary Staff
    • Research Staff
    • Scientific Fellows
    • Senior Research Fellows
    • Associate Membership
  • News
  • Home
  • Our Science
  • Education
    • Postgraduate Research
    • Postgraduate Taught
    • Clinical Academic Training
    • Summer Research Programme
    • Undergraduate
    • Princess Margaret Cancer Centre
  • Impact
    • Videos
    • Seminars and Events
    • Research Engagement
    • Industry and Innovations
    • Bulletins and Annual Reports
  • Opportunities
    • Academic Posts
    • Postdoctoral
    • PhD Opportunities
  • Contact Us
    • Academic Staff
    • Administrative Staff
    • Technical Staff
    • Clinical Academic Training Programme
    • Clinical Research Fellows
    • Honorary Staff
    • Research Staff
    • Scientific Fellows
    • Senior Research Fellows
    • Associate Membership
  • News
  • Our twitter
  • Our facebook
  • Our
  • Home
  • The Patrick G Johnston Centre for Cancer Research
  • Our Science
  • Areas of focus
  • Technology Specialisms
  • Cancer Therapeutics

Cancer Therapeutics

WEB_DAY1+2_575_58
Technology Specialisms
Cancer Therapeutics

Rather than being a single disease, cancer is a heterogeneous collection of diseases. It therefore follows that in order to diagnose and treat cancer effectively, strategies for patient selection must be combined with the development of molecularly targeted therapeutics so that patients can receive the drug or combination of drugs which is most appropriate for the treatment of their disease, at the appropriate time. This approach necessitates the involvement of multi-disciplinary teams of basic researchers and clinicians, working within an infrastructure which allows for effective knowledge transfer across research laboratories, the Northern Ireland Molecular Pathology Lab and Biobank, hospitals and other stakeholders.

The capabilities of the group include:

  • Working with academic groups across the UK, through the CRUK Structural Biology Accelerator programme, to provide access to fragment screening, X-ray crystallography and X-Chem platforms for ‘hit’ identification.
  • Medicinal chemistry expertise in hit to lead, focussed library synthesis and the generation of chemical probes for target validation and chemical biology approaches.
  • The application of nanoparticle-directed drug delivery to enhance therapeutic efficacy and therapeutic index.
  • New training opportunities for graduate students in medicinal and biological chemistry via an exciting new MRes course in Oncology Drug Discovery.

Research is currently focussed in the following areas:

  • Development of new strategies for controlling apoptosis regulation by modulation of the cFLIP and p53 pathways.
  • Developing strategies for the modulation of proteases with a particular focus on Cysteine proteases, including Legumain, Cathepsin S and the Deubiquitinase target class (e.g. USP7, USP17).
  • The development of next generation antibody-based therapeutics
  • Development of novel dUTPase inhibitors to augment 5FU treatments
  • New therapeutic approaches to target RAS and BRAF mutated colorectal cancers
  • Immuno-oncology: Development of new strategies to target the cGAS-STING pathway
  • Targeting the androgen receptor and transcription factors (e.g. c-Myc) in prostate cancer
  • Development of therapeutic strategies to target the DNA Damage Response.
  • The application of new approaches to modulate protein degradation

The multidisciplinary environment within the Centre for Cancer Research and Cell Biology, itself situated within easy reach of other QUB research faculties and Clinical Centres, offers an exciting opportunity for chemists, biologists, geneticists, bioinformaticians, physicists, radiographers and clinicians to combine their expertise to facilitate the drug discovery process.

Principal Investigator Links

Prof Tim Harrison

 Dr Rich Williams

Prof Chris Scott

Prof Dan Longley

Dr Robert Ladner

Dr Ian Overton 

 

close up of researcher using a pipette to place samples in to a container

Research Areas

Technology Specialisms
In This Section
Technology Specialisms
  • Technology Specialisms
Queen's University Belfast - Logo (small)
Contact Us

The Patrick G Johnston Centre for Cancer Research

Queen's University Belfast
97 Lisburn Road
Belfast
BT9 7AE

Phone: +44 (0) 28 9097 2760
Email: pgjccr@qub.ac.uk  
Fax: +44 (0) 28 9097 2776

Quick Links

  • Home
  • Our Science
  • Education

 

© Queen's University Belfast 2021
Legal
Accessibility Statement
Privacy and Cookies
Modern Slavery Statement